CSPC Pharmaceutical Group Limited (CSPC Pharma) will convene a Board of Directors meeting on 27 May 2026 in Hong Kong. The agenda includes approval of the unaudited financial results for the three months ended 31 March 2026, along with other corporate matters.
The meeting will be chaired by Mr. Cai Dong Chen, who heads a 18-member Board comprising 12 executive directors and six independent non-executive directors, as disclosed in the announcement dated 14 May 2026.
The forthcoming first-quarter figures will offer shareholders an early view of CSPC Pharma’s operational performance in 2026 ahead of interim results later in the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments